METHYL 2-METHYL-5-OXO-1,4,5,7-TETRADHYDROFURO3,4- BPYRIDINE-3-CARBOXYLATE COMPOUNDS AS CAV1.2 ACTIVATORS

摘要

The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as Cav1.2 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder, ADHD, Phelan-McDermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease, Brugada Syndrome, Short QT syndrome, and early repolarization syndrome.